Last updated: February 16, 2026
What is NDC 23155-0800?
NDC 23155-0800 identifies a specific medication. Based on available data, it corresponds to Viltolarsen (Viltepso), a drug approved by the U.S. Food and Drug Administration (FDA) in August 2020 for treating Duchenne Muscular Dystrophy (DMD) in patients with specific genetic mutations.
Market Size Overview
Duchenne Muscular Dystrophy (DMD) ranks as a rare disease with significant unmet medical needs. Its prevalence is approximately 1 in 3,500 to 5,000 male live births globally, with an estimated US patient population of roughly 10,000-12,000 under age 20.
- U.S. DMD population: Approximately 8,000-10,000 patients eligible for Viltolarsen.
- US market potential: Based on the prevalence, the target population under treatment guidelines approximates 60-70% of diagnosed patients given mutation-specific therapy.
Market penetration assumptions
- Initial uptake: 10-15% of eligible patients in the first year.
- Growth rate: 15-20% annually over 3-5 years as diagnosis rates improve and treatment access expands.
Current Pricing Landscape
Viltolarsen has received FDA approval via the accelerated pathway, with its pricing structure reflecting its orphan drug status and high R&D costs.
- List price: Approximately $375,000 annually per patient (as of latest market data in 2022-2023).
- Competitive landscape: Other exon skipping therapies include Eteplirsen (Exondys 51) (~$300,000/year), Golodirsen (Vyondys 53) (~$300,000/year), and Casimersen (Amondys 45) (~$300,000/year).
Price Projections
| Year |
Estimated Patients (US) |
Revenue at $375,000 |
Notes |
| 2023 |
800-1,200 |
$300M-$450M |
Early adoption phase, approximately 10-15% of eligible population |
| 2024 |
1,200-1,600 |
$450M-$600M |
Increased access and insurance coverage improve uptake |
| 2025 |
1,800-2,400 |
$675M-$900M |
With expanded diagnosis and awareness, market penetration could approach 25-30% |
| 2026+ |
2,400-3,000 |
$900M-$1.125B |
Potential price adjustments, payer negotiations, and new competitors may influence pricing |
Price Dynamics in the Market
- Pricing pressure: As more exon-skipping agents enter the market, price competition could emerge, potentially reducing list prices to the $250,000-$300,000 range.
- Reimbursement: Insurance coverage remains high for orphan drugs but increasingly requires demonstration of clinical value, pressuring list prices.
- Market growth factors: Advances in early diagnosis, genetic testing, and healthcare infrastructure support market expansion.
Factors Impacting Price and Market Share
- Regulatory developments: Additional approvals or expanded labels for Viltolarsen can increase market access.
- Treatment adherence: The necessity for invasive intramuscular injections, dosing frequency, and side effect management affect patient compliance and retention.
- Competitive activity: Pipeline drugs—such as SRP-4053 and gene editing therapies—may influence future pricing strategies.
Key Takeaways
- NDC 23155-0800 (Viltolarsen) faces a niche but expanding market within the DMD therapeutic landscape.
- Current list prices around $375,000 per year position it among top-tier orphan drugs.
- Market size is constrained but growing, with total US revenue potentially reaching over $1 billion by 2026.
- Price projections depend heavily on competitive dynamics, payer negotiations, and regional market expansions.
- The ongoing development of alternative therapies and gene editing approaches may influence future pricing trends.
FAQs
1. How does Viltolarsen compare to other exon-skipping drugs?
Viltolarsen's list price ($375,000/year) exceeds Exondys 51 and Vyondys 53 (~$300,000/year). Its efficacy profile and mutation-specific approval shape its market position.
2. What factors could lead to a price reduction?
Increased competition, payer pressure, and generics or biosimilars could push prices downward.
3. How many patients are likely to be treated with Viltolarsen annually?
By 2025, roughly 1,800 to 2,400 patients could be under treatment in the US, representing 20-30% of the estimated eligible population.
4. Is international pricing aligned with the US?
No. US prices are often higher owing to market dynamics, reimbursement policies, and health system structures.
5. Are there any upcoming regulatory hurdles impacting Viltolarsen?
Potential label expansions or new approvals could broaden market access but may come with pricing and reimbursement negotiations.
Citations
[1] FDA. "Viltolarsen (Viltepso) Approval Letter." 2020.
[2] EvaluatePharma. "Orphan Drug Pricing Analysis," 2023.
[3] Global Data. "Duchenne Muscular Dystrophy Market Report," 2022.
[4] IQVIA. "Pharmaceutical Pricing and Market Access Data," 2023.
[5] National Institutes of Health. "Duchenne Muscular Dystrophy Fact Sheet," 2022.
